---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-24-000150"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:59:30.045653+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BeiGene Q3 revenue $1.0B (+28% YoY); BRUKINSA global revenue $690M; positive non-GAAP OP income

## Summary
- Total revenue $1,001.6M (+28% YoY); product revenue $993.4M (+67% YoY).
- GAAP operating loss narrowed to $120.3M from $134.0M; adjusted operating income $65.6M vs loss $16.3M.
- BRUKINSA global revenue $690M; now #1 in new patient starts for frontline and R/R CLL in U.S.
- Four NMEs entered clinic in Q3 (eight YTD); on track for 10+ in 2024; sonrotoclax & BGB-16673 in late-stage.
- CEO cites strong momentum in hematology and solid tumor pipeline expansions globally.

## SEC filing metadata
- accession: 0001651308-24-000150
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000150/0001651308-24-000150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000150/bgne-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-24-000150
- JSON: https://secwatch.observer/filing/0001651308-24-000150.json
- Plain text: https://secwatch.observer/filing/0001651308-24-000150.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.